- Company to Host Conference Call and Webcast at 11:00 AM ET Today - NEW YORK and LONDON , Nov. 18, 2025 /PRNewswire/ -- Pearl Diver Credit Company Inc. (NYSE: PDCC, PDPA) (the "Company") today announced financial results for the third quarter ended September 30, 2025. "Despite near-term industry headwinds associated with the First Brands bankruptcy, our portfolio delivered increased sequential recurring cash flows in excess of distributions and expenses," said Indranil Basu, Chief Executive Officer of Pearl Diver Credit Company.

image for news Pearl Diver Credit Company Inc. Announces Third Quarter 2025 Financial Results

The Pop-Tarts Bowl returns with more mascots, more unforgettable moments and more ways to be a part of the action. Key Points: Delivering on two years of fan demand, the 2025 Pop-Tarts Bowl is being dubbed The People's National Championship.

image for news Pop-Tarts® Ups the Ante with 'The Biggest Sacrifice Ever' as Six Edible Mascots Take the Field at the 2025 Pop-Tarts™ Bowl

Live audio webcast available on Dec. 3, 2025, from 12:10 p.m. to 12:45 p.m.

image for news Leidos to participate in the Goldman Sachs Industrials and Materials Conference

NEW YORK , Nov. 18, 2025 /PRNewswire/ -- The following statement is being issued by Labaton Keller Sucharow LLP regarding notice of a proposed class action settlement. UNITED STATES DISTRICT COURT DISTRICT OF ARIZONA IN RE OPENDOOR TECHNOLOGIES INC.

image for news Labaton Keller Sucharow LLP Announces a Proposed Class Action Settlement Involving Purchasers of the Publicly Traded Common Stock of Opendoor Technologies Inc.

BOSTON , Nov. 18, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced its partnership with the Institute for Genomic Biology at the University of Illinois Urbana-Champaign on a five-year initiative funded by the Advanced Research Projects Agency for Health (ARPA-H). The collaboration, Microbe/phage Investigation for Generalized Health TherapY (MIGHTY), aims to develop innovative new treatments for oral health by leveraging Ginkgo's advanced capabilities in working with complex microbial consortia.

image for news Ginkgo Bioworks Partners on Illinois-Led Team to Develop Innovative New Treatments for Oral Health

The objective of this new phase of collaboration with Leiden University Medical Center (LUMC) is to further advance the recently completed and published pioneering research to determine whether the modes of DNA polymerase pol IIIC (PolC) action and resistance are conserved across important species of Gram-positive multidrug resistant organisms The previous LUMC-Acurx Health~Holland project successfully elucidated the structure of PolC from E. faecium, a critical Gram-positive human pathogen, in complex with two Acurx pol IIIC inhibitors.

image for news Health~Holland Awards Another Innovative Research Grant for DNA Pol IIIC Inhibitors to Leiden University Medical Center and Acurx Pharmaceuticals

Enliven Therapeutics remains overvalued relative to its early-stage pipeline progress and current financials. ELVN-001 shows promising safety and efficacy signals in heavily pretreated CML patients, with a pivotal phase 3 trial planned for 2026. ELVN is well-capitalized, with over four years of cash runway, but faces a competitive and relatively small CML market.

image for news Enliven Therapeutics: Notable Early Signals, But Too Many Assumptions To Justify A Buy

Toast: Clover's Stumbles Show Toast's Widening Moat — Neutral

TOST   Seeking Alpha — November 18, 2025

Toast, Inc. (TOST) is upgraded to Strong Buy as its competitive moat widens and growth prospects remain robust. Toast can benefit from the struggles at key competitor Clover, winning more SMB restaurant deals, and deepening strategic partnerships like the recent Uber integration. Management sees clear paths to doubling US market share, is expanding internationally, and entering new verticals, supporting sustained 20%+ revenue growth.

image for news Toast: Clover's Stumbles Show Toast's Widening Moat

MSTY: Understanding Its Performance And Potential — Negative

MSTY   Seeking Alpha — November 18, 2025

YieldMax MSTR Option Income Strategy ETF (MSTY) offers high income via covered calls on volatile MSTR, but has suffered alongside MSTR's decline. MSTY's recent price drop is tied to MSTR's weakness and market volatility, not just NAV erosion, with distributions still attractive for income seekers. MSTY is best used as a small, aggressive allocation within a diversified income portfolio, not as a core holding due to its risk profile.

image for news MSTY: Understanding Its Performance And Potential

President Donald Trump asked McDonald's for more tartar sauce on Filet-O-Fish during D.C. summit and joked about being first former fry cook to be president.

image for news Trump, one of McDonald's 'all time most loyal customers,' offers Filet-O-Fish suggestion

Less Paperwork, More Connected Care: Humana and Epic Advance Data Sharing — Neutral

HUM   Business Wire — November 18, 2025

LOUISVILLE, Ky.--(BUSINESS WIRE)--Humana and Epic advance data sharing through digital innovations that align with federal interoperability priorities and improve patient experience.

image for news Less Paperwork, More Connected Care: Humana and Epic Advance Data Sharing

Fortis: A New Capital Plan Extends Decades Of Dividend Growth — Positive

FTS   Seeking Alpha — November 18, 2025

Fortis Inc. (FTS:CA) unveils a $28.8B, 5-year capital plan targeting 7% annualized rate base growth and continued low-risk project execution. FTS maintains its 52-year dividend growth streak, announcing a 4% increase and targeting 4-6% annual dividend growth through 2030. Recent results highlight stable earnings, strong U.S. operations, and a resilient regulatory profile, supporting Fortis' premium valuation among peers.

image for news Fortis: A New Capital Plan Extends Decades Of Dividend Growth

LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against KBR, Inc. (“KBR” or “the Company”) (NYSE: KBR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of KBR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

image for news KBR, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – KBR

LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against RCI Hospitality Holdings, Inc. (“RCI” or “the Company”) (NASDAQ: RICK) violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of RICK during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments.

image for news RCI Hospitality Holdings, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – RICK

T1 Energy Inc. (TE) Q3 2025 Earnings Call Transcript — Neutral

TE   Seeking Alpha — November 18, 2025

T1 Energy Inc. ( TE ) Q3 2025 Earnings Call November 14, 2025 8:00 AM EST Company Participants Jeffrey Spittel - Executive VP of Investor Relations & Corporate Development Daniel Barcelo - CEO & Chairman Otto Erster Bergesen Evan Calio - Chief Financial Officer Conference Call Participants Philip Shen - ROTH Capital Partners, LLC, Research Division Gregory Lewis - BTIG, LLC, Research Division Sean Milligan - Needham & Company, LLC, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the T1 Energy Third Quarter 2025 Earnings Conference Call.

image for news T1 Energy Inc. (TE) Q3 2025 Earnings Call Transcript

Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026 — Neutral

VTGN   Seeking Alpha — November 18, 2025

Vistagen Therapeutics' intranasal pherine drugs target nose-to-brain circuits. This taps into neuropsychiatric, women's health, and oncology indications. Their lead asset is Fasedienol, which is in Phase 3 for SAD. Its PALISADE-3 data may enable a possible NDA submission during 2026. The rest of VTGN's pipeline includes Itruvone, PH80, and PH284. However, I believe VTGN's tight runway will force them to prioritize Fasedienol's R&D.

image for news Vistagen Therapeutics: Intranasal Pherines And A Make-Or-Break 2026

IREN: A 40% Pullback In A $3.4B ARR Future — Neutral

IREN   Seeking Alpha — November 18, 2025

Iren Limited (IREN) is a rapidly growing dual data center business with a unique blend of Bitcoin mining and AI/HPC hosting operations. IREN's vertical integration, secured 2.9GW power capacity, and strong financing position it well for future growth, despite recent share price volatility. Valuation suggests significant upside potential if execution matches guidance, with a forward P/S ratio becoming attractive by 2027.

image for news IREN: A 40% Pullback In A $3.4B ARR Future

PVH Corp. Announces CFO Transition — Neutral

PVH   Business Wire — November 18, 2025

NEW YORK--(BUSINESS WIRE)--PVH Corp. Announces CFO Transition.

image for news PVH Corp. Announces CFO Transition

Jacobs to Lead Terminal Modernization at Ohio's Busiest Airport — Neutral

J   PRNewsWire — November 18, 2025

Cleveland Hopkins International Airport upgrades to improve critical infrastructure DALLAS , Nov. 18, 2025 /PRNewswire/ -- Jacobs (NYSE: J) has been selected to lead program and construction management services for phase one of a $1.6 billion modernization of Cleveland Hopkins International Airport (CLE). The transformative program, CLEvolution, is designed to reimagine the airport experience for millions of travelers by modernizing aging infrastructure enhancing accessibility and passenger flow at Ohio's most traveled airport.

image for news Jacobs to Lead Terminal Modernization at Ohio's Busiest Airport

Lennar Confirms Expiration Date of Exchange Offer — Neutral

MRP   PRNewsWire — November 18, 2025

Expects Registration Statement to be Effective by Expiration Date MIAMI , Nov. 18, 2025 /PRNewswire/ -- Lennar Corporation (NYSE: LEN and LEN.B) ("Lennar") confirmed today that in view of the reopening of the U.S. federal government, Lennar is proceeding as previously announced with the offer to exchange the approximately 20% of the total outstanding shares of Millrose Properties, Inc. (NYSE: MRP) ("Millrose") it owns for outstanding shares of Lennar Class A common stock (the "Exchange Offer"). The Exchange Offer is scheduled to expire at 12:00 midnight, New York City time, on November 21, 2025 (the "Expiration Date").

image for news Lennar Confirms Expiration Date of Exchange Offer